We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mazor Robotics Renaissance System Study Data Positive
Read MoreHide Full Article
Mazor Robotics Ltd. , an Israel-based developer of robotic technology and products, recently presented data from two clinical studies at a leading Spine Conference. The data demonstrated major clinical benefits of its surgical guidance technological platform.
The studies confirmed an improvement in patient outcomes when surgeons utilized Mazor Robotic’s Renaissance-guidance system. The system guides the surgeon’s instruments to ensure highest levels of accuracy during minimally-invasive surgery (MIS).
The study confirms that usage of robotic guidance in MIS approach can significantly reduce the surgical complications and revision rates compared to both freehand MIS as well as open cases. Notably, these studies corroborate the clinical and economic value proposition of Renaissance system by delivering positive results which meet the surgeon’s expectation.
As per a report by StarTribune, more than 16,000 successful spinal surgeries have been performed worldwide with the Renaissance system, which is a major positive for Mazor Robotics. We believe that the company will continue to win contracts for the same that will propel significant top-line growth.
Meanwhile, Mazor Robotics recently introduced Mazor X, a revolutionary platform for spine surgeries using highly automated robotic technologies. The company is slated to commercially launch the FDA-cleared Mazor X by Oct 2016.
The company also agreed to a commercial co-promotion and co-development deal with Medtronic (MDT - Free Report) , under which the latter has already added 15 Mazor X systems.
Our Take
Mazor Robotics has managed to gain considerable traction in new metropolitan markets and in academic centers within a short span of time.
Internationally, Mazor Robotics continues to work with its distribution partners to expand into the market. On the regulatory front, the company continues to make progress and move closer to approvals in key markets like Japan and South Korea.
Zacks Rank & Key Picks
Mazor Robotics has a Zacks Rank #2 (Buy).
Other favorably ranked stocks in the medical sector are Masimo Corporation (MASI - Free Report) and Mesa Laboratories Inc. (MLAB - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Mazor Robotics Renaissance System Study Data Positive
Mazor Robotics Ltd. , an Israel-based developer of robotic technology and products, recently presented data from two clinical studies at a leading Spine Conference. The data demonstrated major clinical benefits of its surgical guidance technological platform.
The studies confirmed an improvement in patient outcomes when surgeons utilized Mazor Robotic’s Renaissance-guidance system. The system guides the surgeon’s instruments to ensure highest levels of accuracy during minimally-invasive surgery (MIS).
The study confirms that usage of robotic guidance in MIS approach can significantly reduce the surgical complications and revision rates compared to both freehand MIS as well as open cases. Notably, these studies corroborate the clinical and economic value proposition of Renaissance system by delivering positive results which meet the surgeon’s expectation.
As per a report by StarTribune, more than 16,000 successful spinal surgeries have been performed worldwide with the Renaissance system, which is a major positive for Mazor Robotics. We believe that the company will continue to win contracts for the same that will propel significant top-line growth.
MAZOR ROBOTICS Price and Consensus
MAZOR ROBOTICS Price and Consensus | MAZOR ROBOTICS Quote
New Platform for Spinal Surgeries
Meanwhile, Mazor Robotics recently introduced Mazor X, a revolutionary platform for spine surgeries using highly automated robotic technologies. The company is slated to commercially launch the FDA-cleared Mazor X by Oct 2016.
The company also agreed to a commercial co-promotion and co-development deal with Medtronic (MDT - Free Report) , under which the latter has already added 15 Mazor X systems.
Our Take
Mazor Robotics has managed to gain considerable traction in new metropolitan markets and in academic centers within a short span of time.
Internationally, Mazor Robotics continues to work with its distribution partners to expand into the market. On the regulatory front, the company continues to make progress and move closer to approvals in key markets like Japan and South Korea.
Zacks Rank & Key Picks
Mazor Robotics has a Zacks Rank #2 (Buy).
Other favorably ranked stocks in the medical sector are Masimo Corporation (MASI - Free Report) and Mesa Laboratories Inc. (MLAB - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>